^
    Back
    Association details:
    Biomarker:BCR-ABL1 F317L
    Cancer:Acute Lymphocytic Leukemia
    Drug:dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Regimens for relapsed or refractory Ph-positive ALL…Treatment options based on BCR-ABL1 mutation profile…Dasatinib…Contraindicated mutations...T315I/A, F317L/V/I/C, or V299L
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Haematologica
    Title:

    Resistance To Dasatinib In Philadelphia-Positive Leukemia Patients And The Presence Or The Selection Of Mutations At Residues 315 And 317 In The BCR-ABL Kinase Domain

    Excerpt:
    In six of 21 patients, lack of response or relapse were strikingly associated with the presence or the selection of a mutation at codon 317 (F317L in five cases, F317I in one case)….In all patients but one, resistance to dasatinib was invariably found to be associated with mutations at residue 315 and/or at residue 317.
    DOI:
    10.3324/haematol.10822